Resources

New service brings senior regulatory expertise into the early development window, when strategic decisions can have the greatest impact. DLRC, an award-winning global regulatory and market access consultancy that supports the development and licensing of pharmaceutical, biotech, advanced therapy, and medtech products worldwide, launches Regulatory Spark, a new fixed-fee, fast-turnaround service created for early-stage innovators.

Regional cluster updates, fresh OLS data, NICE's Enhertu approval and £89.9m for Chemify - catch up on this week's CEO blog.

Autumn Budget, AI regulation and new transatlantic partnerships: how we’re driving scale and capital for UK biotechs.

LinkGevity is working with Health Innovation East, the NHS innovation arm for the East of England, to advance the clinical pathway for its first-in-class Anti-Necrotic™ therapeutic approach.

Chris Molloy on mRNA cancer vaccine reaching Phase 3 milestone, Scancell MHRA authorisation, microbiome-based medicinal products, MHRA voucher scheme for SMEs, Scotland and data driver projects

The advantages to building a business in the UK's biotech clusters

Aravax today announces it has received Fast Track designation from the US Food and Drug Administration (FDA) for its lead product, PVX108 for the treatment of peanut allergy.

TauRx gathered representatives from leading patient advocacy groups including Alzheimer Europe, Alzheimer Scotland and Alzheimer's Disease International to Scotland House in London.

Theolytics has relocated to ARC Oxford, taking 5,500 SQF at the growing innovation campus.

The Milner Therapeutics Institute has joined the o2h Discovery Platinum Partner Programme, enabling eligible companies within its bio-incubator and wider affiliate network to access specialist drug discovery support through the o2h Kickstarter Award.

Lucideon is expanding its global support for medical device innovation with the launch of a new biocompatibility laboratory in Greenville, South Carolina. Working alongside its UK cell biology laboratory, the new facility will provide a comprehensive range of biocompatibility testing and materials characterisation services from a single source, helping manufacturers accelerate product development, meet regulatory requirements, and bring safer medical devices to market with greater confidence. The investment strengthens Lucideon’s ability to support the next generation of medical technologies, from advanced implants and biomaterials to wearable devices, while helping protect patient safety worldwide. Read the full story to discover how Lucideon is creating a global biocompatibility and materials performance solution for medical device innovators.

Chris Molloy on scale-up policy, improving treatments pipeline, LSSP, GMM regulation, LLSW, MDUK's Pedal Paddle Peak and Dr Sally Ann Forsyth OBE

The UK’s innovative life sciences sector has called on Government to deliver policy continuity, unlock scale-up investment and improve patient access to new medicines.

The challenge of converting scientific progress into real-world access

New AI sandbox will help make medicines safer, speed up development, and reduce reliance on animal testing.

BIA members gathered in London on Tuesday for our 26th annual Parliament Day

Drug Discovery 2026 returns to ExCeL London from 14–15 October to celebrate 20 years of collaboration and inclusion. Keynote programme includes presentation from Dr Sam Barrell CBE and panel discussion with Dr Anne Phelan, Dr Jason Mellad, Prof Sir Mene Pangalos and Prof Raghib Ali OBE

Chris Molloy on Parliament Day, the EU start-up fund, MHRA rare disease regulation, Northern Ireland, women in biotech and scientific leadership